Similar articles

• Phase III randomized trial of docetaxel in combination with cisplatin or carboplatin or vinorelbine plus cisplatin in advanced non--small cell lung cancer: interim analysis.

  Belani C; TAX 326 Study Group. Belani C, et al. Semin Oncol. 2001 Jun;28(3 Suppl 9):10-4. Semin Oncol. 2001. PMID: 11441409 Review.
• Docetaxel combination produces 2-year survival advantage in NSCLC patients.

  [No authors listed] [No authors listed] Oncology (Williston Park). 2001 Dec;15(12):1559, 1564. Oncology (Williston Park). 2001. PMID: 11780700 No abstract available.
• Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group.

  Fossella F, Pereira JR, von Pawel J, Pluzanska A, Gorbounova V, Kaukel E, Mattson KV, Ramlau R, Szczesna A, Fidias P, Millward M, Belani CP. Fossella F, et al. J Clin Oncol. 2003 Aug 15;21(16):3016-24. doi: 10.1200/JCO.2003.12.046. Epub 2003 Jul 1. J Clin Oncol. 2003. PMID: 12837811 Clinical Trial.
• [Chemotherapy for elderly patients with lung cancer].

  Okamoto H, Watanabe K. Okamoto H, et al. Nihon Rinsho. 2002 May;60 Suppl 5:591-5. Nihon Rinsho. 2002. PMID: 12101743 Review. Japanese. No abstract available.
• Docetaxel (Taxotere) and vinorelbine in the treatment of non-small cell lung cancer.

  Georgoulias V, Kourousis C, Androulakis N, Kakolyris S, Papadakis E, Bouros D, Apostolopoulou F, Georgopoulou T, Agelidou M, Souglakos J, Halkiadakis G, Hatzidaki D. Georgoulias V, et al. Semin Oncol. 1997 Aug;24(4 Suppl 14):S14-9-S14-14. Semin Oncol. 1997. PMID: 9335517